Ayala Pharmaceuticals’ treatment of desmoid tumors granted orphan designation, according to a post to the FDA website.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ADXS:
- Ayala Pharmaceuticals presents updated AL102 results at ESMO congress
- Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023
- Ayala Pharmaceuticals closes merger with Biosight
- Ayala Pharmaceuticals Announces Closing of Merger with Biosight